Avago Introduces 25Gbps SerDes IP for Optical, Copper and Backplane Applications

Avago Technologies (Nasdaq:AVGO), a leading supplier of analog interface components for communications, industrial, and consumer applications, today announced that it has demonstrated serial 25Gbps SerDes performance in 40nm CMOS technology. This milestone is the latest achievement in Avago’s history of breakthrough ASIC Intellectual Property (IP) performance.

Key differentiators of Avago’s SerDes cores are its unique decision feedback equalization (DFE), which results in lower overall power usage, as well as best-in-class data latency, noise immunity, jitter, and crosstalk performance. Further, due to Avago’s modular, multi-rate architecture, its SerDes cores are highly integratable, and channel counts in the hundreds are common.

Offering designers great flexibility, Avago’s broad SerDes portfolio is ideal for optical, copper, and backplane applications. Supported standards include PCI Express, Fibre Channel, XAUI, CEI-11G, 10GBASE-KR, and SFI.

“With the demonstration of 25Gbps performance, Avago’s legacy of IP leadership continues,” said Frank Ostojic, vice president and general manager of Avago’s ASIC Products Division. “Our early achievement of this milestone reflects Avago’s ongoing commitment to providing SerDes IP that enables our customers to address the demand for ever-increasing bandwidth.”

With over 95 million SerDes channels shipped, Avago has established a history of delivering reliable, high-performance ASICs. Three decades of design experience, state-of-the art hierarchical design methodology, and an IP portfolio covering multiple standards, form the foundation for success in supplying complex ASICs for networking, computing, and storage applications.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.